Overview

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer. Rifaximin may reduce the incidence and severity of pertuzumab induced gastrointestinal toxicities without interrupting or delaying the chemotherapy schedule.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

National Cancer Institute (NCI)

Treatments:

Pertuzumab
Rifaximin